Aurobindo Pharma's Board will meet on April 6, 2026 to consider a proposal for buyback of fully paid-up equity shares.
The disclosure is made under Regulations 29(1) and 29(2) of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.
Trading window for designated persons was closed from April 1, 2026, and will remain closed until 48 hours post audited results declaration.